Biogen Shares Tumble as Alzheimer's Drug Study Is Halted

Biogen's shares fell over 25% after halting late-stage trials of an Alzheimer's drug. Max Neeson from Bloomberg Opinion explains that this was a major setback for Biogen, which had heavily invested in this approach. The failure highlights the ongoing challenges in Alzheimer's treatment, particularly targeting the amyloid beta protein. The scientific community is increasingly skeptical of this method. Biogen now faces pressure to address other issues, including competition and IP challenges in its multiple sclerosis treatments.

How have previous trial failures influenced investor expectations for Biogen?

What challenges is Biogen facing beyond the halted trials?